Stock research
Viatris Inc. (VTRS) Stock Research
Viatris makes generic and branded medicines distributed across global markets.
Viatris Inc. reported revenue of $14.3B for the fiscal year ended December 31, 2025. Source: Form 10-K filed February 26, 2026
SEC data as of
- Ticker
- VTRS
- Exchange
- NASDAQ
- Sector
- Health
- Founded
- —
Reported SEC XBRL figures. Each metric’s period and original filing are listed below.
Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.
About Viatris
- Exchange
- NASDAQ: VTRS
- Sector
- Health Care
- SEC industry
- Pharmaceutical Preparations (SIC 2834)
- Fiscal year end
- December 31
VTRS key financials
Reported figures from Viatris Inc.'s filings, pulled directly from SEC XBRL data rather than a third-party terminal. Each row links to the filing it came from.
| Metric | Value | Period | Source |
|---|---|---|---|
| Revenue | $14.3B | 2025-01-01 – 2025-12-31 | SEC filing |
| Operating cash flow | $2.3B | 2025-01-01 – 2025-12-31 | SEC filing |
| Diluted EPS | −$3.00 | 2025-01-01 – 2025-12-31 | SEC filing |
| Shares outstanding | 1.15B | As of 2025-11-03 | SEC filing |
Values are as tagged by the issuer in XBRL. Revenue for banks and insurers is net of interest expense where that is the reported line. Fiscal years that do not follow the calendar are shown by their period-end date. No price, market cap, or valuation multiple is shown because Yield Theory does not republish unlicensed market data.
Diluted EPS is the earnings figure behind the price-to-earnings ratio; the P/E multiple compression calculator shows how a change in that multiple moves a share price. Shares outstanding multiplied by the share price gives market capitalization.
What investors should watch in VTRS
Viatris Inc. sits in Health Care. Pharmaceuticals, biotech, medical devices, and managed care — defensive demand paired with binary drug and regulatory catalysts. We have not yet written company-specific drivers for VTRS; the forces that matter most for the sector are:
- ◆Drug approvals and clinical-trial readouts
- ◆Medicare and drug-pricing policy
- ◆Demographics and an aging population
- ◆GLP-1 and obesity-drug demand
VTRS primary sources
- Latest annual report: Form 10-K filed February 26, 2026
- Latest quarterly report: Form 10-Q filed August 6, 2026
- All VTRS filings on SEC EDGAR
How we source and review company pages: research methodology.
Congressional trading in VTRS
| Politician | Trade date | Type | Owner | Amount | Source |
|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-11-18 | Purchase | Self | $1,001 - $15,000 | Filing #20033619 |
| Robert Bresnahan | 2025-04-08 | Sale | Self | $1,001 - $15,000 | Filing #20030291 |
| Gilbert Cisneros | 2025-03-31 | Sale | Self | $1,001 - $15,000 | Filing #20029026 |
| Robert Bresnahan | 2025-02-25 | Purchase | Self | $1,001 - $15,000 | Filing #20029034 |
All verified VTRS congressional disclosures
Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.
Compare VTRS with similar companies
Viatris peers
VTRS — frequently asked questions
What does Viatris Inc. do?
Viatris makes generic and branded medicines distributed across global markets.
What were VTRS's latest reported annual revenue and net income?
Viatris Inc. reported revenue of $14.3B for the fiscal year ended December 31, 2025. The figures come from Viatris Inc.'s SEC XBRL filings.
When does Viatris Inc.'s fiscal year end?
The SEC lists Viatris Inc.'s fiscal year end as December 31.
Do members of Congress trade VTRS?
The current verified House and Senate snapshot contains 4 transaction rows for VTRS, each linked to the original filing.
Is VTRS a good investment?
This page does not rate VTRS as a buy or sell. It sets out what Viatris Inc. reports, what investors should watch and the questions a thesis has to answer, with links to the SEC filings. It is research, not investment advice.
This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.
What do the VTRS numbers leave unanswered?
Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included